FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:542-543 August 12, 1999 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Woloshin, S. PubMed Citation

To the Editor: Woloshin and Schwartz (March 18 issue)¹ recommend against the prostate-cancer stamp on the basis of the conclusion of the U.S. Preventive Services Task Force that there is evidence for excluding prostate-cancer screening from a periodic health examination. Screening, however, largely detects prostate cancer at a curable stage² and not occult cancers, as the authors suggest. Rates of mortality due to prostate cancer in the United States are decreasing in the era of the prostate-specific–antigen assay (after 30 years of steady increases), and the declines are associated with groups that avail themselves of screening and with regions where . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.